Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection. Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) rece...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2021-09, Vol.32 (9), p.2147-2152
Hauptverfasser:	Bertrand, Dominique, Hamzaoui, Mouad, Lemée, Veronique, Lamulle, Julie, Hanoy, Mélanie, Laurent, Charlotte, Lebourg, Ludivine, Etienne, Isabelle, Lemoine, Mathilde, Le Roy, Frank, Nezam, Dorian, Plantier, Jean-Christophe, Boyer, Olivier, Guerrot, Dominique, Candon, Sophie
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Viral - biosynthesis BNT162 Vaccine Cohort Studies COVID-19 - complications COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - pharmacology Female Humans Immunocompromised Host Immunosuppressive Agents - adverse effects Kidney Failure, Chronic - complications Kidney Failure, Chronic - immunology Kidney Failure, Chronic - therapy Kidney Transplantation - adverse effects Male Middle Aged Pandemics Rapid Communications Renal Dialysis Retrospective Studies RNA, Messenger - genetics SARS-CoV-2 - genetics SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology T-Lymphocytes - immunology Transplant Recipients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection. Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs. After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies (
ISSN:	1046-6673 1533-3450 1533-3450
DOI:	10.1681/ASN.2021040480